Regeneron Pharmaceuticals Inc - $REGN STOCK NEWS

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will be participating in investor conferences including the RBC Capital Markets Global Healthcare Conference, Jefferies Global Healthcare Conference, and Goldman Sachs 45th Annual Global Healthcare Conference. The webcasts can be accessed on the company's website, with replays available for 30 days.

Regeneron reported first quarter 2024 financial results with revenues decreasing 1% to $3.15 billion; excluding Ronapreve, revenues increased 7%. Dupixent global net sales rose 24% to $3.08 billion, EYLEA U.S. net sales were $1.40 billion, and Libtayo global net sales increased 45% to $264 million. The company announced a $3.0 billion share repurchase program. Regeneron is progressing well in delivering medicines, advancing its pipeline, and pursuing cutting-edge science, particularly in retinal diseases, oncology, and potential regulatory approvals. Financially, GAAP net income decreased by 12% and non-GAAP diluted EPS decreased by 5%. The company is focusing on innovation and returned $298 million to shareholders through share repurchases.

Regeneron Pharmaceuticals, Inc. announced positive long-term results from the EYLEA HD clinical program, showcasing durable efficacy and safety in patients with retinal diseases. The data presented at ARVO highlight the potential of EYLEA HD as a new standard of care for wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. Notable presentations include results from the PHOTON and PULSAR trials, demonstrating maintained visual improvements with EYLEA HD.

Regeneron Pharmaceuticals, Inc. (REGN) and Mammoth Biosciences, Inc. collaborate to advance in vivo CRISPR-based gene editing therapies for multiple diseases. Regeneron's AAV vectors and Mammoth's ultracompact gene editing systems aim to target tissues beyond the liver. Mammoth receives $100 million upfront payment and equity investment, with potential milestone payments totaling up to $370 million per target. Regeneron gains access to Mammoth's editing technologies for a period of five and a half years.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will showcase new data and updates on its oncology and hematology pipeline at the ASCO 2024 Annual Meeting. The presentations will cover investigational treatments for a variety of solid tumors and blood cancers, including REGN7075, a promising costimulatory bispecific antibody in combination with Libtayo. The company's commitment to cancer research and development of innovative therapies is evident in the diverse pipeline of checkpoint inhibitors and bispecific antibodies being presented at the conference.

Regeneron Pharmaceuticals, Inc. to showcase genetic medicine research advancements at ASGCT conference, including results from clinical study of otoferlin gene therapy DB-OTO for genetic hearing loss. The company will present data on delivery systems, immune response modulation, and sustained treatment expression. Regeneron aims to overcome obstacles in genetic medicine implementation through innovative approaches. Promising early results from gene therapy programs raise hope for future treatments.

Regeneron Pharmaceuticals, Inc. presents positive pivotal data on linvoseltamab for relapsed/refractory multiple myeloma at AACR Annual Meeting 2024. The data show promising results with high response rates, durable responses, and good safety profile.

Regeneron Pharmaceuticals, Inc. (REGN) will report its Q1 2024 financial results on May 2, 2024. A conference call and webcast will be held at 8:30 AM Eastern Time. Participants can join via webcast or telephone.

SillaJen submits CSR to the US FDA for REN026, a study on Pexa-Vec and cemiplimab in RCC patients. The study shows positive safety and efficacy results, with high response rates and overall survival. Collaboration with Regeneron Pharmaceuticals yields promising outcomes.